- Cellular Origins and Fresenius Kabi have partnered to integrate Fresenius Kabi’s cell therapy technologies within Cellular Origins’ robotic platform.
- The collaboration aims to improve manufacturing efficiency and reduce errors in the cell and gene therapy production process.
Cellular Origins and Fresenius Kabi have signed a development agreement to integrate Fresenius Kabi’s cell therapy processing technologies into Cellular Origins’ robotic manufacturing platform, Constellation. This collaboration is expected to enhance manufacturing efficiency for cell and gene therapies (CGTs), helping developers produce therapies at scale while reducing human error.
The partnership focuses on incorporating Fresenius Kabi’s Cue system into Constellation, with future plans to integrate other tools like the Lovo Cell Processing System. By automating key processes, the companies aim to alleviate the risks of human variation, improving production consistency.
Dr Edwin Stone, CEO of Cellular Origins, noted the importance of collaborations to industrialize CGT manufacturing: “We are working closely with [Fresenius Kabi] to unlock the power of automation throughout the entire manufacturing process, with the goal of bringing life-saving therapies to patients, faster and more affordably.”
Dr Christian Hauer, President MedTech at Fresenius Kabi, emphasised the role of automation in addressing production challenges: “Our cell therapy technologies are designed with automation at their core…we hope to advance the CGT industry by helping therapy developers embrace automation during the production process.”
Overview of outsourcing trends 
